Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Signal transducer and activator of transcription (Stat) 3 is an oncogene constitutively activated in many cancer systems where it contributes to carcinogenesis. To develop chemical probes that selectively target Stat3, we virtually screened 920,000 small drug-like compounds by docking each into the peptide-binding pocket of the Stat3 SH2 domain, which consists of three sites--the pY-residue binding site, the +3 residue-binding site and a hydrophobic binding site, which served as a selectivity filter. Three compounds satisfied criteria of interaction analysis, competitively inhibited recombinant Stat3 binding to its immobilized pY-peptide ligand and inhibited IL-6-mediated tyrosine phosphorylation of Stat3. These compounds were used in a similarity screen of 2.47 million compounds, which identified 3 more compounds with similar activities. Examination of the 6 active compounds for the ability to inhibit IFN-gamma-mediated Stat1 phosphorylation revealed that 5 of 6 were selective for Stat3. Molecular modeling of the SH2 domains of Stat3 and Stat1 bound to compound revealed that compound interaction with the hydrophobic binding site was the basis for selectivity. All 5 selective compounds inhibited nuclear-to-cytoplasmic translocation of Stat3, while 3 of 5 compounds induced apoptosis preferentially of breast cancer cell lines with constitutive Stat3 activation. Thus, virtual ligand screening of compound libraries that targeted the Stat3 pY-peptide binding pocket identified for the first time 3 lead compounds that competitively inhibited Stat3 binding to its pY-peptide ligand; these compounds were selective for Stat3 vs. Stat1 and induced apoptosis preferentially of breast cancer cells lines with constitutively activated Stat3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 1×
“Furthermore, human tumor xenograft studies in mice have repeatedly demonstrated that inhibiting Stat3 results in decreased tumor growth and improved animal survival [4] by inducing apoptosis in tumor cells, inhibiting angiogenesis [9] and enhancing anti-tumor immune-mediated cytotoxicity [2,10].”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“Thus, Stat3 has been identified as a potentially high-yield target for drug development to treat many cancers [11–13].”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465 · cited 2×
“While Stat3 contributes to oncogenesis, in part, through inhibition of apoptosis, Stat1 is anti-oncogenic; it mediates the apoptotic effects of interferons and contributes to tumor immunity [14,34].”
BackgroundStattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
STAT proteins: novel molecular targets for cancer drug discovery
Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504 · cited 7×
“Best-fit curves were determined using 4- Parameter Logistic Model/Dose Response/XLfit 4.2, IDBS software and were used to calculate the IC50 values (Table 2). doi:10.1371/journal.pone.0004783.g004 PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4783 MDA-MB-468 (panel A), MDA-MB-231 (panel B), MDA-MB-43…”
BackgroundInfluentialValidating Stat3 in cancer therapy
Darnell, J. E. (2005) · Nature Medicine · doi:10.1038/nm0605-595 · Cited by 307 · cited 1×
“Thus, Stat3 has been identified as a potentially high-yield target for drug development to treat many cancers [11–13].”
BackgroundHuang, Y., Qiu, J., Dong, S., Redell, M. S., Poli, V., Mancini, M. A., & Tweardy, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704548200 · Cited by 65
Self-citation
Cited by
Ballester, P. J., & Mitchell, J. B. O. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq112 · Cited by 989
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Therapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“STAT3 inhibitors identified by structure-based highthroughput virtual screening include STA-21, Stattic (Stat three-inhibitory compound), S3I-201/NSC74859, BP-1-102, OPB-31121, TTI-101 (C188-9), and their analogs.”
BackgroundInfluentialSelf-citationStat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass
Zhang, L., Pan, J., Dong, Y., Tweardy, D. J., Dong, Y., Garibotto, G., & Mitch, W. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.07.012 · Cited by 263
Self-citationRedell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B., & Tweardy, D. J. (2011) · Blood · doi:10.1182/blood-2010-04-280123 · Cited by 257
Self-citationSilva, K. A. S., Dong, J., Dong, Y., Dong, Y., Schor, N., Tweardy, D. J., Zhang, L., & Mitch, W. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641514 · Cited by 229
Self-citationSTAT3 in the systemic inflammation of cancer cachexia
Zimmers, T. A., Fishel, M. L., & Bonetto, A. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.02.009 · Cited by 225
Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., & Agarwal, S. K. (2016) · The FASEB Journal · doi:10.1096/fj.15-273953 · Cited by 193
“C-188-9 is a synthetic small molecule STAT-3 inhibitor that targets the phospho-Tyr peptide binding pocket within the STAT-3 Src homology 2 domain (36, 55) and inhibits STAT-3 activation-receptor recruitment and homodimerization (37).”
BackgroundSelf-citationTargeting Cancer Stem Cells in Triple-Negative Breast Cancer
Park, S.-Y., Choi, J.-H., & Nam, J.-S. (2019) · Cancers · doi:10.3390/cancers11070965 · Cited by 192
“This clinical trial is currently recruiting patients with advanced cancers, including breast cancer [103].”
BackgroundPan, Y., Zhou, F., Zhang, R., & Claret, F. X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054565 · Cited by 132
Jung, K. H., Yoo, W., Stevenson, H. L., Deshpande, D., Shen, H., Gagea, M., Yoo, S.-Y., Wang, J., Eckols, T. K., Bharadwaj, U., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2253 · Cited by 124
“Clin Cancer Res; 23(18) September 15, 2017 Clinical Cancer Research 5544”
BackgroundInfluentialSelf-citationLewis, K. M., Bharadwaj, U., Eckols, T. K., Kolosov, M., Kasembeli, M. M., Fridley, C., Siller, R., & Tweardy, D. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.014 · Cited by 63
Self-citationHaggie, P. M., Cil, O., Lee, S., Tan, J.-A., Rivera, A. A., Phuan, P.-W., & Verkman, A. S. (2018) · JCI Insight · doi:10.1172/jci.insight.121370 · Cited by 56
“Another 3-acetic acid-coumarin was reported to inhibit the oncogene signal transducer and activator of transcription (Stat3) activation by inhibiting the nuclear translocation of phosphorylated Stat3 (44).”
BackgroundMinus, M. B., Liu, W., Vohidov, F., Kasembeli, M. M., Long, X., Krueger, M. J., Stevens, A., Kolosov, M. I., Tweardy, D. J., Sison, E. A. R., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506889 · Cited by 38
Self-citation
Metadata
- Authors
- Xu, X., Kasembeli, M. M., Jiang, X., Tweardy, B. J., & Tweardy, D. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-03-10
- Volume
- 4
- Issue
- 3
- Pages
- e4783
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2117862793
- Cited by
- 129
- References
- 11
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.